Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Grc 3886
2. Grc-3886
3. Grc3886
1. 778576-62-8
2. N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methylsulfonamido)dibenzo[b,d]furan-1-carboxamide
3. Oglemilast [inn]
4. 67gxq6wcc6
5. N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide
6. Grc 3845
7. Grc 3886
8. Unii-67gxq6wcc6
9. Grc-3886
10. Oglemilast [who-dd]
11. Schembl220245
12. Chembl4297520
13. Dtxsid70999058
14. Grc3886
15. Bcp21392
16. Zinc72266998
17. Cs-0844
18. Db12375
19. Ncgc00379066-01
20. Hy-15178
21. Grc 3886;grc-3886;grc3886
22. A853039
23. Q27264129
24. 4-difluoromethoxy-8-methanesulfonylamino-dibenzofuran-1-carboxylic Acid (3,5-dichloro-pyridin-4-yl)-amide
25. N-(3,5-dichloropyridin-4(1h)-ylidene)-4-(difluoromethoxy)-8-[(methanesulfonyl)amino]dibenzo[b,d]furan-1-carboxamide
26. N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-((methylsulfonyl)amino)dibenzo(b,d)furan-1-carboxamide
| Molecular Weight | 516.3 g/mol |
|---|---|
| Molecular Formula | C20H13Cl2F2N3O5S |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 6 |
| Exact Mass | 514.9921034 g/mol |
| Monoisotopic Mass | 514.9921034 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 810 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Oglemilast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oglemilast, including repackagers and relabelers. The FDA regulates Oglemilast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oglemilast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Oglemilast supplier is an individual or a company that provides Oglemilast active pharmaceutical ingredient (API) or Oglemilast finished formulations upon request. The Oglemilast suppliers may include Oglemilast API manufacturers, exporters, distributors and traders.
Oglemilast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oglemilast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oglemilast GMP manufacturer or Oglemilast GMP API supplier for your needs.
A Oglemilast CoA (Certificate of Analysis) is a formal document that attests to Oglemilast's compliance with Oglemilast specifications and serves as a tool for batch-level quality control.
Oglemilast CoA mostly includes findings from lab analyses of a specific batch. For each Oglemilast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oglemilast may be tested according to a variety of international standards, such as European Pharmacopoeia (Oglemilast EP), Oglemilast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oglemilast USP).
LOOKING FOR A SUPPLIER?
